Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Boeing’s 737 Max Is Critical to Its Future

By Chris Lau, InvestorPlace Contributor

Boeing stock could rebound to the $300 level if the coronavirus subsides, air traffic returns to normal and the 737 Max returns to flight.

Aphria Needs Strong Sales Growth to Rise High Again

By Chris Lau, InvestorPlace Contributor

What does the future look like for Aphria stock? It depends on its success in growing market share and international sales.

Here’s Why Qualcomm Stock Is Worth Over $100 Now

By Chris Lau, InvestorPlace Contributor

The upside for Qualcomm stock depends on revenue growth, accelerated by the industry transitioning from 4G to 5G.

7 Energy Stocks That Are Too Cheap to Ignore

By Chris Lau, InvestorPlace Contributor

A failed OPEC deal and a Saudi oil price war had energy stocks tanking on Monday. But long-term investors should jump into the sector now.

Its Powerful Pipeline Shows Pfizer Stock Is Undervalued by 15%

By Chris Lau, InvestorPlace Contributor

Pfizer stock is gearing up for a strong 2020 as the company spins out is generics drug business, completing a merger with Mylan.

Load More